566 related articles for article (PubMed ID: 28533357)
21. Polymorphonuclear-MDSCs Facilitate Tumor Regrowth After Radiation by Suppressing CD8
Zhang Md J; Zhang Md L; Yang Md Y; Liu Md Q; Ma Md H; Huang Md A; Zhao Md Y; Xia Md Z; Liu Md T; Wu Md G
Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1533-1546. PubMed ID: 33238192
[TBL] [Abstract][Full Text] [Related]
22. PMN-MDSCs Enhance CTC Metastatic Properties through Reciprocal Interactions via ROS/Notch/Nodal Signaling.
Sprouse ML; Welte T; Boral D; Liu HN; Yin W; Vishnoi M; Goswami-Sewell D; Li L; Pei G; Jia P; Glitza-Oliva IC; Marchetti D
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31003475
[TBL] [Abstract][Full Text] [Related]
23. Polymorphonuclear MDSCs are enriched in the stroma and expanded in metastases of prostate cancer.
Wen J; Huang G; Liu S; Wan J; Wang X; Zhu Y; Kaliney W; Zhang C; Cheng L; Wen X; Lu X
J Pathol Clin Res; 2020 Jul; 6(3):171-177. PubMed ID: 32149481
[TBL] [Abstract][Full Text] [Related]
24. Tumor-induced myeloid-derived suppressor cell subsets exert either inhibitory or stimulatory effects on distinct CD8+ T-cell activation events.
Schouppe E; Mommer C; Movahedi K; Laoui D; Morias Y; Gysemans C; Luyckx A; De Baetselier P; Van Ginderachter JA
Eur J Immunol; 2013 Nov; 43(11):2930-42. PubMed ID: 23878002
[TBL] [Abstract][Full Text] [Related]
25. Regulation of ROS in myeloid-derived suppressor cells through targeting fatty acid transport protein 2 enhanced anti-PD-L1 tumor immunotherapy.
Adeshakin AO; Liu W; Adeshakin FO; Afolabi LO; Zhang M; Zhang G; Wang L; Li Z; Lin L; Cao Q; Yan D; Wan X
Cell Immunol; 2021 Apr; 362():104286. PubMed ID: 33524739
[TBL] [Abstract][Full Text] [Related]
26. Subsets of myeloid-derived suppressor cells in hepatocellular carcinoma express chemokines and chemokine receptors differentially.
Zhao W; Xu Y; Xu J; Wu D; Zhao B; Yin Z; Wang X
Int Immunopharmacol; 2015 Jun; 26(2):314-21. PubMed ID: 25891236
[TBL] [Abstract][Full Text] [Related]
27. Serum-resistant CpG-STAT3 decoy for targeting survival and immune checkpoint signaling in acute myeloid leukemia.
Zhang Q; Hossain DM; Duttagupta P; Moreira D; Zhao X; Won H; Buettner R; Nechaev S; Majka M; Zhang B; Cai Q; Swiderski P; Kuo YH; Forman S; Marcucci G; Kortylewski M
Blood; 2016 Mar; 127(13):1687-700. PubMed ID: 26796361
[TBL] [Abstract][Full Text] [Related]
28. Myeloid-Derived Suppressor Cells Impair B Cell Responses in Lung Cancer through IL-7 and STAT5.
Wang Y; Schafer CC; Hough KP; Tousif S; Duncan SR; Kearney JF; Ponnazhagan S; Hsu HC; Deshane JS
J Immunol; 2018 Jul; 201(1):278-295. PubMed ID: 29752311
[TBL] [Abstract][Full Text] [Related]
29. Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy.
Sun L; Clavijo PE; Robbins Y; Patel P; Friedman J; Greene S; Das R; Silvin C; Van Waes C; Horn LA; Schlom J; Palena C; Maeda D; Zebala J; Allen CT
JCI Insight; 2019 Apr; 4(7):. PubMed ID: 30944253
[TBL] [Abstract][Full Text] [Related]
30. Identification and characterization of B220
Zhang Z; Huang X; Wang E; Huang Y; Yang R
Oncoimmunology; 2021 Apr; 10(1):1912472. PubMed ID: 33948392
[TBL] [Abstract][Full Text] [Related]
31. Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy.
Zhou J; Liu M; Sun H; Feng Y; Xu L; Chan AWH; Tong JH; Wong J; Chong CCN; Lai PBS; Wang HK; Tsang SW; Goodwin T; Liu R; Huang L; Chen Z; Sung JJ; Chow KL; To KF; Cheng AS
Gut; 2018 May; 67(5):931-944. PubMed ID: 28939663
[TBL] [Abstract][Full Text] [Related]
32. Repression of MUC1 Promotes Expansion and Suppressive Function of Myeloid-Derived Suppressor Cells in Pancreatic and Breast Cancer Murine Models.
Sahraei M; Bose M; Sanders JA; De C; DasRoy L; Nath S; Brouwer CR; Mukherjee P
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070449
[TBL] [Abstract][Full Text] [Related]
33. Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3.
Trovato R; Fiore A; Sartori S; Canè S; Giugno R; Cascione L; Paiella S; Salvia R; De Sanctis F; Poffe O; Anselmi C; Hofer F; Sartoris S; Piro G; Carbone C; Corbo V; Lawlor R; Solito S; Pinton L; Mandruzzato S; Bassi C; Scarpa A; Bronte V; Ugel S
J Immunother Cancer; 2019 Sep; 7(1):255. PubMed ID: 31533831
[TBL] [Abstract][Full Text] [Related]
34. The spleen contributes to the increase in PMN-MDSCs in orthotopic H22 hepatoma mice.
Li BH; Jiang W; Zhang S; Huang N; Sun J; Yang J; Li ZF
Mol Immunol; 2020 Sep; 125():95-103. PubMed ID: 32659598
[TBL] [Abstract][Full Text] [Related]
35. Immunotherapy Targeting Myeloid-Derived Suppressor Cells (MDSCs) in Tumor Microenvironment.
Gao X; Sui H; Zhao S; Gao X; Su Y; Qu P
Front Immunol; 2020; 11():585214. PubMed ID: 33613512
[TBL] [Abstract][Full Text] [Related]
36. Loss of MyD88 leads to more aggressive TRAMP prostate cancer and influences tumor infiltrating lymphocytes.
Peek EM; Song W; Zhang H; Huang J; Chin AI
Prostate; 2015 Apr; 75(5):463-73. PubMed ID: 25597486
[TBL] [Abstract][Full Text] [Related]
37. Targeting and exploitation of tumor-associated neutrophils to enhance immunotherapy and drug delivery for cancer treatment.
Zhang Y; Guoqiang L; Sun M; Lu X
Cancer Biol Med; 2020 Feb; 17(1):32-43. PubMed ID: 32296575
[TBL] [Abstract][Full Text] [Related]
38. Expression profiles and function of IL6 in polymorphonuclear myeloid-derived suppressor cells.
Ibrahim ML; Lu C; Klement JD; Redd PS; Yang D; Smith AD; Liu K
Cancer Immunol Immunother; 2020 Nov; 69(11):2233-2245. PubMed ID: 32488308
[TBL] [Abstract][Full Text] [Related]
39. Pseudoneutrophil Cytokine Sponges Disrupt Myeloid Expansion and Tumor Trafficking to Improve Cancer Immunotherapy.
Li S; Wang Q; Shen Y; Hassan M; Shen J; Jiang W; Su Y; Chen J; Bai L; Zhou W; Wang Y
Nano Lett; 2020 Jan; 20(1):242-251. PubMed ID: 31790598
[TBL] [Abstract][Full Text] [Related]
40. Myeloid-derived suppressor cells are essential partners for immune checkpoint inhibitors in the treatment of cisplatin-resistant bladder cancer.
Takeyama Y; Kato M; Tamada S; Azuma Y; Shimizu Y; Iguchi T; Yamasaki T; Gi M; Wanibuchi H; Nakatani T
Cancer Lett; 2020 Jun; 479():89-99. PubMed ID: 32200039
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
